ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Novadaq Data Presented At 2008 Society Of Thoracic Surgeons Meeting
Novadaq(R) Technologies Inc.
(TSX: NDQ), a developer of real-time medical imaging systems and image
guided therapies for the operating room, announced that independent
data on SPY(R) and PINPOINT(TM) was presented at an educational program for
cardiothoracic surgeons. The event, co-hosted with four other medical
device companies, took place during the 44th Annual Society of Thoracic
Surgery (STS) meeting which was held January 26th - January 30th, 2008 in
Fort Lauderdale, Florida. The STS represents the largest gathering of
cardiothoracic surgeons in the world and is considered the premiere global
meeting.
The invitation-only event included comprehensive presentations and open
discussions by cardiac and thoracic surgeons highlighting the latest
medical therapies and technologies. Novadaq's products, the SPY
Intra-operative Imaging System and the PINPOINT Autofluorescence Endoscopic
Imaging System, were featured in two of the five key presentations:
- Autofluorescence Brochoscopy and Photodynamic Therapy: A Thoracic
Surgeon's Perspective by Patrick Ross Jr., M.D., Ph.D., Associate
Professor and Director of Thoracic Surgery at Ohio State University
and Director of Thoracic Oncology at the Arthur G. James Cancer
Hospital in Columbus, Ohio
- SPY Intra-Operative Imaging in Graft Assessment by David Paul
Taggart, M.D., Ph.D., FRCS, Professor of Cardiovascular Surgery for
the John Radcliffe Hospital in Oxford, UK
Dr. Patrick Ross stressed the clinical importance of using
autofluorescence imaging to provide guidance during endoluminal and
traditional surgical treatments for lung cancer. Dr. Ross reported the use
of real-time autofluorescence bronchoscopy, compared to the gold standard
white light bronchoscopy, provides for a more detailed assessment of the
patient's anatomy before pulmonary resection, a more accurate assessment
for the presence of early lung cancers and the ability to more precisely
perform endoluminal therapies such as Photodynamic Therapy. Dr. Ross also
reminded the cardiothoracic surgeon audience that autofluorescence
bronchoscopy is now recommended in the 2008 American College of Chest
Physicians Evidence Based Practice Guidelines for use in detecting
cancerous lesions and for guiding surgical treatments in patients with lung
cancer.
Professor Taggart reported his clinical experience using the SPY
Intra-operative Imaging System to optimize the clinical outcomes of his
coronary artery bypass procedures, which have been previously published in
the literature and confirm the need for intra-operative graft assessment.
Professor Taggart's presented clinical results of studies he has performed
using SPY. Data reported by others indicating that as many as 30% of all
vein grafts may be closed at 1 year post bypass were also included.
Professor Taggart stressed that coronary artery disease has become more
complex, making coronary artery bypass surgery more technically demanding,
which further increases the need for real-time assessment of graft quality.
Professor Taggart reported on studies of the clinical utility of available
technologies for graft assessment, including a report by Nimesh Desai, MD.,
et.al, published in The Journal of Thoracic and Cardiovascular Surgery in
2006. The randomized study compared SPY and the Transit Time Flow Meter,
the two most commonly used tools, to the gold standard x-ray angiography.
In the study of 139 bypass grafts, SPY was found to result in 83%
sensitivity and 100% specificity compared to 25% and 94% respectively for
the Transit Time Flow Meter.
"Our presence at STS 2008 represents the progress our company has made
over the past 12 months. Last year at STS we had only our SPY System to
offer and we had just hired our first few direct sales representatives,"
said Dr. Arun Menawat, President and Chief Executive Officer of Novadaq
Technologies Inc. "Today we have expanded our offerings to include the
Heart Laser(TM) System for TMR and our PINPOINT Endoscopic Imaging System
and have a fully engaged sales organization covering the entire US. The
feedback from our surgeon customers like Drs. Ross and Taggart continues to
confirm that our products contribute to the overall technical success of
their procedures and that image guidance ultimately does facilitate optimal
treatment strategies and improve clinical outcomes for patients."
About Novadaq Technologies
Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes
medical imaging systems and real-time image guided therapies for use in the
operating room. Novadaq's proprietary ICG imaging systems can be used to
visualize blood vessels, nerves and the lymphatic system during a variety
of surgical procedures. Novadaq's SPY Imaging System, commercially
available worldwide, enables cardiac surgeons to visually assess coronary
vasculature and bypass graft functionality during the course of heart
bypass surgery. The SPY System is expandable to include upgrade kits for
use during other surgeries such as other cardiovascular, plastic,
reconstructive and organ transplant surgery allowing surgeons to evaluate
blood flow and tissue and organ perfusion. In addition, SPY is ideal for
use during urological procedures enabling surgeons to visualize vessels,
tumors, the lymphatic system and potentially nerve bundles. Novadaq's
OPTTX(R) System is aimed at the diagnosis, evaluation and treatment of wet
Age-related Macular Degeneration (AMD) by using the same core imaging
technology that is used in the SPY Imaging System. Novadaq also offers the
FDA approved PINPOINT endoscopic system for visualizing native tissue
fluorescence which allows surgeons to differentiate between healthy and
cancerous tissue in the lung during thoracic surgery. Novadaq is also the
exclusive United States distributor of PLC Medical's CO2 HEART LASER(TM)
System for TMR (Trans-Myocardial Revascularization). For more information,
please visit the company's website at http://www.novadaq.com.
Forward looking Statements
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance
or achievements to be materially different from those implied by such
statements, and therefore these statements should not be read as guarantees
of future performance or results. All forward-looking statements are based
on Novadaq's current beliefs as well as assumptions made by and information
currently available to Novadaq and relate to, among other things, results
of future clinical tests of PINPOINT and the SPY System, anticipated
financial performance, business prospects, strategies, regulatory
developments, market acceptance and future commitments. Readers are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by Novadaq
in its public securities filings actual events may differ materially from
current expectations. Novadaq disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Novadaq Technologies Inc.
http://www.novadaq.com
View drug information on Photodynamic Therapy.
Novadaq Datele prezentate la 2008 Thoracic Society of Surgeons Meeting - Novadaq Data Presented At 2008 Society Of Thoracic Surgeons Meeting - articole medicale engleza - startsanatate